Name: Telatinib (BAY 57-9352)
Price: 290.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    Telatinib (BAY 57-9352) is a selective inhibitor of VEGFR2, VEGFR3, c-Kit and PDGFRα with IC50 value of 6 nM, 4 nM, 1 nM and 15 nM, respectively [1].
    Vascular endothelial growth factor receptor (VEGFR) is the receptor of VEGF and plays an important role in stimulating vasculogenesis and angiogenesis. Platelet-derived growth factor (PDGF) is a member of growth factors and involves in blood vessel formation. C-Kit is the receptor of a growth factor. Many studies have shown that abnormal of VEGFR, c-Kit and PDGFR are correlated with a variety of tumors [1, 2, 3].
    Telatinib is a potent VEGFR2/3, c-Kit and PDGFRα inhibitor. When tested with a panel of tumor cell lines (MDA-MB-231 breast caicinoma, Colo-205 colon carcinoma, DLD-1 colon carcinoma and H460 non-small cell lung carcinoma), Telatinib treatment exhibited inhibition on VEGFR-2 autophosphorylation and PDGF-βwhich involved in the angiogenic process [2].
    Telatinib has been used in clinical trails to a variety of cancers treatment and has achieved promising results [2-4].
    It is also reported that Telatinib restores tumor cells sensitivity to anticancer drugs and significantly reduced cellular viability by inhibiting ABCG2 expression [3].
    
    [1]. Steeghs, N., et al., Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res, 2008. 14(11): p. 3470-6.
    [2]. Strumberg, D., et al., Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours. Br J Cancer, 2008. 99(10): p. 1579-85.
    [3]. Sodani, K., et al., Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo. Biochem Pharmacol, 2014. 89(1): p. 52-61.
    [4]. Eskens, F.A., et al., Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors. J Clin Oncol, 2009. 27(25): p. 4169-76.
- Properties
  - Alternative Name
    
    BAY 579352;BAY 57 9352; 4-[[4-(4-chloroanilino)furo[2,3-d]pyridazin-7-yl]oxymethyl]-N-methylpyridine-2-carboxamide
    
    CAS Number
    
    332012-40-5
    
    Molecular Formula
    
    C20H16ClN5O3
    
    Molecular Weight
    
    409.83
    
    Appearance
    
    A solid
    
    Purity
    
    98.00%
    
    Solubility
    
    insoluble in H2O; insoluble in EtOH; ≥20.5 mg/mL in DMSO
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only

Telatinib (BAY 57-9352)

Telatinib (BAY 57-9352)

Background

We Also Recommend

Dapivirine (TMC120)

INK 128 (MLN0128)

PTC124 (Ataluren)